EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic effect of two antimicrobial peptides, BP203 and MAP-0403 J-2 with conventional antibiotics against colistin-resistant Escherichia coli and Klebsiella pneumoniae clinical isolates

Chawalit Chatupheeraphat iD, Jiratchaya Peamchai, Sirirat Luk-In, Sakda Yainoy iD, Warawan Eiamphungporn iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0294287 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Chawalit Chatupheeraphat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research Innovation and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Salaya, Nakhon Pathom, Thailand. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Colistin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mahidol University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-resistant Enterobacterales infections are a great health concern due to the lack of effective treatments. Consequently, finding novel antimicrobials or combining therapies becomes a crucial approach in addressing this problem. BP203 and MAP-0403 J-2, novel antimicrobial peptides, have exhibited effectiveness against Gram-negative bacteria. In this study, we assessed the in vitro antibacterial activity of BP203 and MAP-0403 J-2, along with their synergistic interaction with conventional antibiotics including colistin, rifampicin, chloramphenicol, ceftazidime, meropenem, and ciprofloxacin against colistin-resistant Escherichia coli and Klebsiella pneumoniae clinical isolates. The minimal inhibitory concentrations (MIC) of BP203 and MAP-0403 J-2 against tested E . coli isolates were 2–16 and 8–32 μg/mL, respectively. However, for the majority of K . pneumoniae isolates, the MIC of BP203 and MAP-0403 J-2 were >128 μg/mL. Notably, our results demonstrated a synergistic effect when combining BP203 with rifampicin, meropenem, or chloramphenicol, primarily observed in most K . pneumoniae isolates. In contrast, no synergism was evident between BP203 and colistin, chloramphenicol, ceftazidime, rifampicin, or ciprofloxacin when tested against all E . coli isolates. Furthermore, synergistic effects between MAP-0403 J-2 and rifampicin, ceftazidime or colistin were observed against the majority of E . coli isolates. Similarly, the combined effect of MAP-0403 J-2 with rifampicin or chloramphenicol was synergistic in the majority of K . pneumoniae isolates. Importantly, these peptides displayed the stability at high temperatures, across a wide range of pH values, in specific serum concentrations and under physiological salt conditions. Both peptides also showed no significant hemolysis and cytotoxicity against mammalian cells. Our findings suggested that BP203 and MAP-0403 J-2 are promising candidates against colistin-resistant E . coli . Meanwhile, the synergism of these peptides and certain antibiotics could be of great therapeutic value as antimicrobial drugs against infections caused by colistin-resistant E . coli and K . pneumoniae .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsColistinEscherichia coliKlebsiella pneumoniaeCeftazidimeMeropenemRifampinAntimicrobial PeptidesDrug SynergismChloramphenicolCiprofloxacinMicrobial Sensitivity Tests

Substanzen

Anti-Bacterial AgentsColistinCeftazidimeMeropenemRifampinAntimicrobial PeptidesChloramphenicolCiprofloxacin

Autor:innen und Institutionen

  • Center for Research Innovation and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Salaya, Nakhon Pathom, Thailand.
  • Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand.

ORCID-Profile: Chawalit Chatupheeraphat, Sakda Yainoy, Warawan Eiamphungporn

Förderung

  • Mahidol University

Zitieren

APA

Chatupheeraphat, C., Peamchai, J., Luk-In, S., Yainoy, S., & Eiamphungporn, W. (2023). Synergistic effect of two antimicrobial peptides, BP203 and MAP-0403 J-2 with conventional antibiotics against colistin-resistant Escherichia coli and Klebsiella pneumoniae clinical isolates. PLOS ONE. https://doi.org/10.1371/journal.pone.0294287

Vancouver

Chatupheeraphat C, Peamchai J, Luk-In S, Yainoy S, Eiamphungporn W. Synergistic effect of two antimicrobial peptides, BP203 and MAP-0403 J-2 with conventional antibiotics against colistin-resistant Escherichia coli and Klebsiella pneumoniae clinical isolates. PLOS ONE. 2023. doi:10.1371/journal.pone.0294287

BibTeX
@article{Chatupheeraphat2023,
  author = {Chatupheeraphat, Chawalit and Peamchai, Jiratchaya and Luk-In, Sirirat and Yainoy, Sakda and Eiamphungporn, Warawan},
  title = {Synergistic effect of two antimicrobial peptides, BP203 and MAP-0403 J-2 with conventional antibiotics against colistin-resistant Escherichia coli and Klebsiella pneumoniae clinical isolates},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0294287}
}
Kostenlos starten →